Suvica is a biotechnology company that is focused on the discovery and development of small molecules for the treatment of cancer. Currently, they have a small molecule protein synthesis inhibitor in pre-clinical development. SVC112 – With a patent filed for Composition of Matter protection, SVC112 has shown pre-clinical efficacy as monotherapy and in combination with standard therapies such as radiation and newly approved targeted agents. SVC112 is in pre-clinical development for a variety of cancer indications, including head & neck cancer, melanoma, colorectal cancer, and non-small cell lung cancer. It was founded in 2010 and is headquartered in Boulder, Colorado.

Research Grants 4 show all


$249.6K
2013

$1.4M
2015

$297.6K
2017

$1.9M
2019

Patents 6show all

  • 5
    A61K - Preparations for medical, dental, or toilet purposes
  • 5
    C07K - Peptides
  • 4
    A61N - Electrotherapy

Contact Information

Boulder, CO
United States

Overview

Total FundingEmployeesLast Funding DateStatus
1-10Operating